U.S. 最高裁判所 拒絶するs 特許 控訴，上告 over Cubicin 麻薬
By Lawrence Hurley
WASHINGTON, May 31 (Reuters) - The U.S. 最高裁判所 on Tuesday 拒絶するd Cubist 製薬のs Inc's 企て，努力，提案 to 生き返らせる four 特許s for its 抗生物質 麻薬 Cubicin, 覆うing the way for 競争相手 Hospira Inc to introduce a generic 見解／翻訳／版 as soon as this year.
The high 法廷，裁判所 left in place a November 判決，裁定 by the U.S. 法廷，裁判所 of 控訴，上告s for the 連邦の 回路・連盟 支持するing a 地裁 判決，裁定 無効のing four of five 特許s held by Merck & Co Inc-owned Cubist, which were challenged by Pfizer Inc-owned Hospira.
The 控訴，上告s 法廷，裁判所 decided that four of the 特許s, 満了する／死ぬing in 2019 and 2020, were 無効の, and that one, 満了する／死ぬing in June of this year, was valid, meaning Hospira can move 今後 with 計画（する）s for a generic 見解／翻訳／版 of the 麻薬.
Cubicin is an 抗生物質 注射 used in hospitals to 扱う／治療する bacterial 肌 感染s. (報告（する）／憶測ing by Lawrence Hurley; Editing by Will Dunham)
